LUND UNIVERSITY

Ceylon cinnamon does not affect postprandial plasma glucose or insulin in subjects with impaired glucose tolerance.

Wickenberg, Jennie; Lindstedt Ingemansson, Sandra; Berntorp, Kerstin; Nilsson, Jan; Hlebowicz, Joanna

Link to publication

Total number of authors:
5

Ceylon cinnamon does not affect postprandial plasma glucose or insulin in subjects with impaired glucose tolerance

Jennie Wickenberg[1,2], Sandra Lindstedt[3], Kerstin Berntorp[4], Jan Nilsson[1,2] and Joanna Hlebowicz[1,2,5]*

[1]*Center for Emergency, Skåne University Hospital, Lund University, Malmö, Sweden*
[2]*Department of Clinical Science, Lund University, Malmö, Sweden*
[3]*Department of Cardio-thoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden*
[4]*Department of Endocrinology, Skåne University Hospital, Lund University, Malmö, Sweden*
[5]*Department of Cardiology, Skåne University Hospital, Entrance 35, SE-205 02 Malmö, Sweden*

Abstract

Previous studies on healthy subjects have shown that the intake of 6 g *Cinnamomum cassia* reduces postprandial glucose and that the intake of 3 g *C. cassia* reduces insulin response, without affecting postprandial glucose concentrations. Coumarin, which may damage the liver, is present in *C. cassia*, but not in *Cinnamomum zeylanicum*. The aim of the present study was to study the effect of *C. zeylanicum* on postprandial concentrations of plasma glucose, insulin, glycaemic index (GI) and insulinaemic index (GII) in subjects with impaired glucose tolerance (IGT). A total of ten subjects with IGT were assessed in a crossover trial. A standard 75 g oral glucose tolerance test (OGTT) was administered together with placebo or *C. zeylanicum* capsules. Finger-prick capillary blood samples were taken for glucose measurements and venous blood for insulin measurements, before and at 15, 30, 45, 60, 90, 120, 150 and 180 min after the start of the OGTT. The ingestion of 6 g *C. zeylanicum* had no significant effect on glucose level, insulin response, GI or GII. Ingestion of *C. zeylanicum* does not affect postprandial plasma glucose or insulin levels in human subjects. The Federal Institute for Risk Assessment in Europe has suggested the replacement of *C. cassia* by *C. zeylanicum* or the use of aqueous extracts of *C. cassia* to lower coumarin exposure. However, the positive effects seen with *C. cassia* in subjects with poor glycaemic control would then be lost.

Key words: Glucose: Insulin: Ceylon cinnamon: Impaired glucose tolerance

The cinnamon tree is a member of the laurel family. Cinnamon is the inner bark of the cinnamon tree and is used as a spice. Ceylon cinnamon, with the botanical name *Cinnamomum zeylanicum/verum* is also known as 'true cinnamon'. However, the related *Cinnamomum cassia/aromataticus*, *Cinnamomum burmannii* and *Cinnamomum loreirii* are also sold as cinnamon. According to an investigation of various herbs and medicinal plants, *C. cassia* and *C. zeylanicum* extracts are among the most effective in the regulation of blood glucose *in vitro*[1]. A water-soluble polyphenol type-A polymer, isolated from *C. burmannii*, has been shown to enhance insulin action by stimulating the insulin receptor *in vitro*[2,3]. The effects on insulin sensitivity of different species of cinnamon, *C. cassia*, *C. burmannii*, *C. loreirii* and *C. zeylanicum*, have been reported not to differ[2]. However, in another experiment it was found that extract of *C. cassia* had a better effect on glucose and insulin levels in rats than an extract of *C. zeylanicum*[4]. In a previous study on healthy subjects, we found that the ingestion of 6 g *C. cassia* powder reduced the postprandial glucose concentration and gastric emptying rate[5]. We also found that an intake of 3 g *C. cassia* powder reduced postprandial insulin concentrations more noticeably than the ingestion of 1 g *C. cassia* powder, without affecting the postprandial glucose level or the gastric emptying rate in healthy subjects[6]. However, ingestion of capsules containing the equivalent of 5 g *C. cassia* powder 12 h before, or in conjunction with, an oral glucose test in healthy men has been found to reduce the glucose response, while no difference was observed in the insulin response[7]. The intake of capsules corresponding to 3 g *C. cassia* powder the night before an oral glucose tolerance test (OGTT) has been found to reduce the glucose response in healthy men, while no difference was observed in the insulin response[8]. These effects were lost within 2 d of ceasing cinnamon intake after 2 weeks of daily *C. cassia* ingestion[8].

Abbreviations: AUC, area under the curve; GI, glycaemic index; GII, glycaemic insulinaemic index; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test.

* **Corresponding author:** J. Hlebowicz, fax +46 40 92 32 72, email joanna.hlebowicz@med.lu.se

Evidence of the positive effect of *C. cassia* supplementation on glycaemic control in people with type 2 diabetes is still inconclusive. Owing to the presence of a toxic component called coumarin, the Federal Institute for Risk Assessment (BrF) in Europe has recently warned against consuming large amounts of *C. cassia* powder. On the basis of experimental studies on hepatotoxicity in dogs[9], the BrF established that 0·1 mg coumarin/kg body weight per d could be ingested over a lifetime without posing a risk to health. In more recent studies on the use of coumarin as a medical product, nine out of 114 patients exhibited elevated levels of transaminases in serum[10–12]. Analyses of cinnamon powder have shown levels of coumarin between 0·7 and 12·2 g/kg spice[13,14]. True Ceylon cinnamon, *C. zeylanicum*, has negligible amounts of coumarin[4,14]. The BrF has therefore suggested the replacement of *C. cassia* by *C. zeylanicum*, or the use of aqueous extracts of *C. cassia* in order to lower coumarin exposure. However, the effects of *C. zeylanicum* on glucose and insulin levels have not previously been studied in human subjects.

Changes in lifestyle, such as increased energy intake and decreased physical activity, are causing overweight and obesity, leading to an epidemical increase in type 2 diabetes. Low glycaemic index (GI) and/or low glycaemic load diets are associated with a reduced risk of type 2 diabetes[15], comparable with the risk reduction observed with a high intake of dietary fibre and whole-grain products. The GI was originally introduced by Jenkins *et al.*[16] to classify carbohydrate-containing foods according to their effects on blood glucose. The GI is defined as the increase in the area under the curve (AUC) over 2 h, above the fasting blood glucose, after the ingestion of a test meal, divided by the response to a reference meal such as white bread or glucose[17]. Impaired glucose tolerance (IGT) is associated with increased risk of developing type 2 diabetes[18]. Studies suggest that IGT is associated with muscle insulin resistance and defective insulin secretion, resulting in less efficient disposal of the glucose load during the OGTT[19]. Type 2 diabetes can be prevented by changes in the lifestyles of subjects with IGT[20]. The present study was therefore designed to determine whether *C. zeylanicum* lowered postprandial glucose, insulin levels, GI and glycaemic insulinaemic index (GII) in subjects with IGT.

Experimental methods

A total of ten subjects with IGT (six male, four female; age 61 (SD 16) years (range 29–73 years); BMI 26·3 (SD 4·2) kg/m^2 (range 20·1–32·7 kg/m^2)) were included in the present cross-over study. All subjects were recruited from the population in southern Sweden. Patients were selected for the present study on the basis of the diagnosis of IGT (fasting glucose <7·0 mmol/l, 2 h venous glucose ≥7·8 mmol/l and <11 mol/l). Glucose tolerance status and fasting plasma glucose levels were evaluated using the criteria established by the WHO[18]. A standard 75 g OGTT was performed within 12 months before enrolment. Subjects who had thyroid disorders, or who had taken insulin or oral anti-diabetic drugs within 60 d before enrolment were excluded. Four subjects were

smokers. The fasting glucose concentration of each subject was checked on the day of the examination to ensure that it was normal (<7·0 mmol/l).

Capsules containing either 560 mg lactose (Apoteket, Produktion & Laboratorier, Gothenburg, Sweden) or 400 mg *C. zeylanicum* and 100 mg lactose (Svampbutiken; Mediapoint AB, Västerås, Sweden) were prepared in advance by the Malmö University Hospital Pharmacy. Although both cinnamon and placebo capsules appeared identical, it is possible that some of the participants could discern a difference between the two types of capsules. The subjects were examined between 07.30 and 10.30 hours after a 12 h fast. Smoking and snuff taking were prohibited 8 h before and during the test. The OGTT consisted of 75 g glucose to which 6·9 g lactose was added, and was ingested with fifteen capsules containing *C. zeylanicum*. The reference OGTT consisted of 75 g glucose, and was ingested with fifteen placebo capsules. The OGTT were served in random order at intervals of 1 week. Randomisation was performed using a table of random numbers.

Finger-prick capillary blood samples were taken to determine glucose levels, and venous blood for the determination of insulin concentrations, before and at 15, 30, 45, 60, 90, 120, 150 and 180 min after the start of the OGTT. Glucose concentrations were measured with the HemoCue Glucose system (HemoCue AB, Ängelholm, Sweden), which converts blood glucose to plasma-equivalent glucose concentrations by multiplying by a constant factor of 1·11[21]. The precision of the HemoCue Glucose system was better than 0·3 SD between 0 and 22·2 mmol/l. Insulin concentrations were measured using an immunoassay with an alkaline phosphatase conjugate (Access Ultrasensitive Insulin; Beckman-Coulter AB, Bromma, Sweden). The sensitivity of the insulin immunoassay was 0·03 mU/l, and the intra-assay CV was less than 10 % in the interval 0·03–300 mU/l.

All subjects gave their written informed consent. The present study was approved by the Ethics Committee of Lund University, and was performed according to the Helsinki Declaration. The present study started on 11 May 2009 and ended on 11 September 2009. The trial registration no. is NCT01027585.

The incremental AUC were measured for plasma glucose and insulin in each subject using GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA, USA). The AUC above the baseline was calculated. The GI and the GII were calculated from the 0–180 min AUC using each subject as their own reference. The GI and GII were calculated by expressing the increase in glucose level of each participant following the test meal as a percentage of the same participant's response after the reference meal. All statistical calculations were performed using SPSS for Windows (version 14.0, 2005; SPSS, Inc., Chicago, IL, USA). Differences in the plasma glucose levels, insulin levels and glycaemic index were evaluated with Wilcoxon's *t* test. Values of $P<0·05$ were considered significant. Differences in GI in ten subjects can be detected with 80 % power at a level of $P<0·05$.

Results

No significant differences were seen in glucose responses at different time periods, or in the incremental areas under the postprandial glucose curves, between the OGTT with and without *C. zeylanicum* (Fig. 1, Table 1). Neither were any significant differences seen in insulin responses at different time periods nor in the incremental areas under the postprandial insulin curves, between the OGTT with and without *C. zeylanicum* (Fig. 2, Table 1). No significant differences were seen in GI or GII between the meals with and without *C. zeylanicum* (Table 1).

Discussion

The aim of the present study was to elucidate the effect of *C. zeylanicum* on postprandial glucose and insulin levels in subjects with IGT. The present hypothesis was that an intake of *C. zeylanicum* would lower the postprandial glucose and insulin response. We were not able to verify this hypothesis. The present findings agree with those of Verspohl *et al.*[4] who found that the effect of extract of *C. cassia* on glucose and insulin in rats was superior to that of the extract of *C. zeylanicum*. However, the effects of *C. zeylanicum* on glucose and insulin levels have not been studied previously in human subjects. Regarding cinnamon, a distinction must be made between *C. zeylanicum* and *C. cassia*. *C. zeylanicum* contains hardly any coumarin in contrast to *C. cassia*[22]. Administration of coumarin to diabetic rats indicates alterations in the metabolism of glucose, resulting in a reduction in plasma glucose levels[23,24]. It has also been suggested that coumarin may change the glucose metabolism in the rat liver, leading to reduced plasma glucose levels[25]. The effects of coumarin on glucose and insulin levels in human subjects have not been reported. However, it can be assumed that coumarin ingestion will also affect glucose metabolism in human

Table 1. Postprandial plasma glucose area under the curve (AUC), plasma insulin AUC, the glycaemic index (GI) and insulinaemic index (GII) in subjects with impaired glucose tolerance following an oral glucose tolerance test (OGTT) with placebo capsules or *Cinnamomum zeylanicum* capsules*

(Mean values with their standard errors, *n* 10)

	OGTT with placebo capsules		OGTT with *C. zeylanicum* capsules	
	Mean	SEM	Mean	SEM
GI	100		98	10
Glucose AUC (mmol/l per min)				
0–150 min	668·0	84·5	615·6	56·2
0–180 min	709·5	85·3	659·2	64·5
GII	100		109	15
Insulin AUC (mU/l per min)				
0–150 min	7512·7	1987·5	7668·0	1785·2
0–180 min	8523·6	2236·5	8834·4	2167·8

* Mean values were not significantly different between postprandial blood glucose AUC, plasma insulin AUC, the GI and GII when evaluated with Wilcoxon's *t* test.

subjects. In a total of forty-four *C. cassia* samples from various Asian countries, He *et al.*[13] identified levels of more than 1 g coumarin per kg dry cinnamon powder in ten samples; the maximum level measured was 12·2 g/kg. Miller *et al.*[14] reported coumarin levels from below the detection level to 0·19 g/kg in twelve *C. zeylanicum* samples, and between 0·7 and 12·2 g/kg in twelve *C. cassia* samples. Unfortunately, the coumarin levels or structure in cinnamon powder were not measured in the present study or in our previous studies on the effects of cinnamon on glucose and plasma lipids in patients with type 2 or type 1 diabetes and in healthy human subjects. Studies on animals indicate that, depending on the structure of coumarins, there may be diverse toxicity[26]. Coumarin is poorly soluble in water, and the BrF has therefore suggested the replacement of *C. cassia* by aqueous extracts of *C. cassia* to lower coumarin exposure.

In a study in Pakistan by Khan *et al.*[27], it was found that the ingestion of 1, 3 and 6 g *C. cassia* powder daily for 40 d lowered the levels of fasting glucose, TAG, LDL-cholesterol and total cholesterol in women and men with type 2 diabetes receiving oral glucose-lowering treatment. Mang *et al.*[28] found that treating women and men with type 2 diabetes with oral glucose-lowering medication or diet and/or physical activity and 3 g aqueous extract of *C. cassia* daily for 4 months resulted in a reduction in fasting plasma glucose levels, while no difference was observed in HbA1c, total cholesterol, LDL, HDL or TAG concentration. Vanschoonbeek *et al.*[29] found no improvement in HbA1c, fasting glucose or insulin concentration, TAG, LDL, HDL, total cholesterol or insulin resistance or sensitivity in overweight, postmenopausal women with type 2 diabetes, following either oral blood-glucose-lowering medication or controlled diets supplemented with 1·5 g *C. cassia* powder per d for 6 weeks. In a study performed in the USA, Blevins *et al.*[30] found no significant changes in fasting glucose, lipid, HbA1c or insulin levels in people

Fig. 1. Plasma glucose concentration in ten subjects with impaired glucose tolerance following an oral glucose tolerance test with placebo capsules (reference; ■) or *Cinnamomun zeylanicum* capsules (◆). Values are means with their standard errors represented by vertical bars. Mean values were not significantly different between the two conditions when evaluated with Wilcoxon's *t* test.

Fig. 2. Plasma insulin concentration in ten subjects with impaired glucose tolerance following an oral glucose tolerance with placebo capsules (reference; ■) or *Cinnamomun zeylanicum* capsules (◆). Values are means with their standard errors represented by vertical bars. Mean values were not significantly different between the two conditions when evaluated with Wilcoxon's *t* test.

with type 2 diabetes when 1 g *C. cassia* powder was consumed daily for 3 months. In the study in Pakistan by Khan, the fasting serum glucose concentrations of the subjects were between 11·4 and 16·7 mmol/l, which is approximately HbA1c values of 8·0–10·5 %[27]. These results suggest that those with poorly controlled diabetes may benefit from cinnamon intake more than those receiving adequate treatment. Patients with type 1 diabetes treated with 1 g *C. cassia* powder per d for 3 months showed no difference in HbA1c, total daily insulin intake or number of hypoglycaemic episodes compared with the placebo group[31]. This may be explained by the fact that cinnamon decreases insulin resistance, which is not involved in the pathology of type 1 diabetes. However, a recent meta-analysis of the above-mentioned five randomised, placebo-controlled trials on patients with type 1 and type 2 diabetes did not show any significant changes in HbA1c, fasting glucose or lipid levels[32]. In women with polycystic ovary syndrome without diabetes, a dietary supplement of 333 mg *C. burmannii* extract, three times a day for 8 weeks, has been found to lower insulin resistance and fasting glucose levels[33]. A dietary supplement of 1·5 g *C. cassia* powder for 12 weeks in subjects with type 2 diabetes led to no significant changes in HbA1c, fasting glucose or lipid levels[34].

Conclusions

The insulin-like biological activity of different species of cinnamon, *C. cassia, C. burmannii, C. loreirii* and *C. zeylanicum*, has been reported not to be different *in vitro* in rat epididymal fat cells[3], and the BrF has suggested the replacement of *C. cassia* by *C. zeylanicum*, or the use of aqueous extracts of *C. cassia* to lower coumarin exposure for human subjects. However, the results of the present study show that the ingestion of *C. zeylanicum* does not affect postprandial plasma glucose or insulin levels in human subjects.

References

1. Broadhurst CL, Polansky MM & Anderson RA (2000) Insulin-like biological activity of culinary and medicinal plant aqueous extracts *in vitro. J Agric Food Chem* **48**, 849–852.
2. Anderson RA, Broadhurst CL, Polansky MM, *et al.* (2004) Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. *J Agric Food Chem* **52**, 65–70.
3. Imparl-Radosevich J, Deas S, Polansky MM, *et al.* (1998) Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: implication for cinnamon regulation of insulin signalling. *Horm Res* **50**, 177–182.
4. Verspohl EJ, Bauer K & Neddermann E (2005) Antidiabetic effect of *Cinnamomum cassia* and *Cinnamomum zeylanicum in vivo* and *in vitro. Phytother Res* **19**, 203–206.
5. Hlebowicz J, Darwiche G, Björgell O, *et al.* (2007) Effect of cinnamon on postprandial blood glucose, gastric emptying and satiety in healthy subjects. *Am J Clin Nutr* **85**, 1552–1556.
6. Hlebowicz J, Hlebowicz A, Lindstedt S, *et al.* (2009) Effect of 1 and 3 g cinnamon on postprandial blood glucose, insulin, GIP, GLP-1, ghrelin, gastric emptying and satiety in healthy subjects. *Am J Clin Nutr* **89**, 815–821.
7. Solomon TPJ & Blannin AK (2007) Effects of short-term cinnamon ingestion on *in vivo* glucose tolerance. *Diabetes Obes Metab* **9**, 895–901.
8. Solomon TPJ & Blannin AK (2009) Changes in glucose tolerance and insulin sensitivity following 2 weeks of daily cinnamon ingestion in healthy humans. *Eur J Appl Physiol* **105**, 969–976.
9. Hagan EC, Hansen WH, Fitzhugh OG, *et al.* (1967) Food flavouring and compounds related structure. II. Subacute and chronic toxicity. *Food Cosmet Toxicol* **5**, 141–157.
10. Burian M, Freudenstein J, Tegtmeier M, *et al.* (2003) Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. *Int J Clin Pharmacol Ther* **41**, 141–147.
11. Schmeck-Lindenau HJ, Naser-Hijazi B, Becker EW, *et al.* (2003) Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study. *Int J Clin Pharmacol Ther* **41**, 193–199.
12. Vanscheidt W, Rabe E, Naser-Hijazi B, *et al.* (2002) The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. *Vasa* **31**, 185–190.
13. He ZD, Qiao CF, Han QB, *et al.* (2005) Authentication and quantitative analysis on the chemical profile of cassia bark

(cortex cinnamomi) by high-pressure liquid chromatography. *J Agric Food Chem* **53**, 2424–2428.

14. Miller KG, Poole CF & Chichila TMP (1995) Solvent-assisted supercritical fluid extraction for the isolation of semivolatile flavor compounds from the cinnamons of commerce and their separation by series-coupled column gas chromatography. *J High Resol Chromatogr* **18**, 461–471.

15. Barclay AW, Petocz P, McMillan-Price J, et al. (2008) Glycemic index, glycemic load, and chronic disease risk – a meta-analysis of observation studies. *Am J Clin Nutr* **87**, 627–637.

16. Jenkins DJ, Wolever TM, Taylor RH, et al. (1981) Glycemic index of foods: a physiological basis for carbohydrate exchange. *Am J Clin Nutr* **34**, 362–366.

17. American Diabetes Association (2007) Nutrition recommendations and interventions for diabetes. A position statement of the American Diabetes Association. *Diabetes Care* **30**, S48–S65.

18. World Health Organization (1999) *Definition, Diagnosis, and Classification of Diabetes Mellitus and Intermediate Hyperglycemia; Report of WHO Consultation. Part 1.* Geneva: WHO.

19. Abdul-Ghani MA, Jenkinson CP, Richardson DK, et al. (2006) Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance. Results from the Veterans Administration Genetic Epidemiology Study. *Diabetes* **55**, 1430–1435.

20. Tuomilehto J, Lindstrom J, Eriksson JG, et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* **344**, 1343–1350.

21. Burnett RW, D'Orazio P, Fogh-Andersen N, et al. (2001) Scientific Division, Working Group on Selective Electrodes: IFCC recommendation on reporting results for blood glucose. *Clin Chim Acta* **307**, 205–209.

22. Jayatilaka A, Poole SW, Poole CF, et al. (1995) Simultaneous micro steam distillation/solvent extraction for the isolation of semivolatile flavor compounds from cinnamon and their separation by series coupled-column gas chromatography. *Anal Chim Acta* **302**, 147–162.

23. Pari L & Rajarajeswari N (2009) Efficacy of coumarin on hepatic key enzymes of glucose metabolism in chemical induced type 2 diabetic rats. *Chem Biol Interact* **181**, 292–296.

24. Guerrero-Analco JA, Hersch-Martínez P, Pedraza-Chaverri J, et al. (2005) Antihyperglycemic effect of constituents from *Hintonia standleyana* in streptozotocin-induced diabetic rats. *Planta Med* **71**, 1099–1105.

25. Feuer G, Golberg L & Gibson KI (1996) Liver response tests. VII. Coumarin metabolism in relation to the inhibition of rat-liver glucose 6-phosphatase. *Food Cosmet Toxicol* **4**, 157–167.

26. Kleiner HE, Xia X, Sonoda J, et al. (2008) Effects of naturally occurring coumarins on hepatic drug-metabolizing enzymes in mice. *Toxicol Appl Pharmacol* **232**, 337–350.

27. Khan A, Safdar M, Ali Khan MM, et al. (2003) Cinnamon improves glucose and lipids of people with type 2 diabetes. *Diabetes Care* **26**, 3215–3218.

28. Mang B, Wolters M, Schmitt B, et al. (2006) Effect of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. *Eur J Clin Invest* **36**, 340–344.

29. Vanschoonbeek K, Thomassen BJW, Senden JM, et al. (2006) Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patient. *J Nutr* **136**, 977–980.

30. Blevins SM, Leyva MJ, Brown J, et al. (2007) Effect of cinnamon and lipid levels in non-insulin dependent type 2 diabetes mellitus. *Diabetes Care* **30**, 2236–2237.

31. Altschuler JA, Casella SM, MacKenzie TA, et al. (2007) The effect of cinnamon on A1C among adolescent with type 1 diabetes. *Diabetes Care* **30**, 813–816.

32. Baker WLB, Gutiereez-Williams G, White CM, et al. (2008) The effect of cinnamon on glucose control and lipid parameters. *Diabetes Care* **31**, 41–43.

33. Wang JG, Anderson RA, Graham GM, et al. (2007) The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study. *Fertil Steril* **88**, 240–243.

34. Suppapitiporn S, Kanpaksi N & Suppapitiporn S (2006) The effect of cinnamon cassia powder in type 2 diabetes mellitus. *J Med Assoc Thai* **89**, Suppl. 3, S200–S205.